A Bioabsorbable Everolimus-Eluting Coronary Stent System for Patients With Single De-Novo Coronary Artery Lesions - ABSORB: 6-month and 2-year results

Description:

The goal of the trial was to evaluate use of a bioabsorbable drug-eluting stent (DES) platform among patients undergoing elective percutaneous coronary intervention (PCI) for a de novo coronary lesion.